Synonym
T-705-RTP; T705RTP; T 705 RTP; T-705RTP; T 705RTP; T705-RTP; T705 RTP
IUPAC/Chemical Name
((2R,3S,4R,5R)-5-(3-carbamoyl-5-fluoro-2-oxopyrazin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate
InChi Key
UUKPXXBDUCDZDA-KAFVXXCXSA-N
InChi Code
InChI=1S/C10H15FN3O15P3/c11-4-1-14(9(18)5(13-4)8(12)17)10-7(16)6(15)3(27-10)2-26-31(22,23)29-32(24,25)28-30(19,20)21/h1,3,6-7,10,15-16H,2H2,(H2,12,17)(H,22,23)(H,24,25)(H2,19,20,21)/t3-,6-,7-,10-/m1/s1
SMILES Code
FC(N=C1C(N)=O)=CN([C@@H]2O[C@H](COP(O)(OP(O)(OP(O)(O)=O)=O)=O)[C@@H](O)[C@H]2O)C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
529.16
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang Y, Yuan C, Xu X, Chong TH, Zhang L, Cheung PP, Huang X. The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription. Biophys Chem. 2021 Oct;277:106652. doi: 10.1016/j.bpc.2021.106652. Epub 2021 Jun 25. PMID: 34237555.
2: Huchting J, Vanderlinden E, Van Berwaer R, Meier C, Naesens L. Cell line- dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. doi: 10.1016/j.antiviral.2019.04.002. Epub 2019 Apr 2. PMID: 30951731.
3: Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, Symons J, Behera I, Rajwanshi VK, Dyatkina N, Wang G, Beigelman L, Deval J. Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases. Antimicrob Agents Chemother. 2015 Dec;59(12):7504-16. doi: 10.1128/AAC.01391-15. Epub 2015 Sep 21. PMID: 26392512; PMCID: PMC4649231.
4: Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 2013 Oct;84(4):615-29. doi: 10.1124/mol.113.087247. Epub 2013 Aug 1. PMID: 23907213.
5: Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguus base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One. 2013 Jul 10;8(7):e68347. doi: 10.1371/journal.pone.0068347. PMID: 23874596; PMCID: PMC3707847.
6: Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus- infected cells. J Antimicrob Chemother. 2009 Oct;64(4):741-6. doi: 10.1093/jac/dkp274. Epub 2009 Jul 29. PMID: 19643775; PMCID: PMC2740635.
